PRIME MEDICINE INC. -

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 11 2024 15:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

06 11 2024 15:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

24 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Unveils Strategically Focused Pipeline

30 9 2024 06:01:00 提供 Nasdaq GlobeNewswire

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

30 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

10 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

08 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

01 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

29 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

23 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

01 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

28 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

20 2 2024 15:01:00 提供 Nasdaq GlobeNewswire

Prime Medicine Announces Pricing of Upsized Public Offering

14 2 2024 22:50:13 提供 Nasdaq GlobeNewswire

Prime Medicine Announces Proposed Public Offering of Common Stock

14 2 2024 15:05:00 提供 Nasdaq GlobeNewswire